Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy

Nananda F. Col, Jerry H. Gurwitz, Joseph S Alpert, Robert J. Goldberg

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The purpose of this study was to determine the extent to which patients with cardiogenic shock have participated in trials of thrombolytic therapy, to examine factors associated with their exclusion from these trials, and to summarize data on the efficacy of thrombolysis in these patients. Previous publications were searched for all randomized, controlled studies involving the use of thrombolytic medications used in the treatment of acute myocardial infarction. Data were abstracted for year of trial publication, performance location, sample size, maximal allowable delay between symptom onset and treatment, and exclusion criteria. Of the 94 trials included in the analysis, 22% included patients with cardiogenic shock, 37% excluded them, and the remainder contained no information on their inclusion or exclusion. Only 2 trials provided data on the efficacy of thrombolytic therapy in patients with cardiogenic shock. Multivariate analysis revealed that studies conducted exclusively in the U.S. were significantly more likely to exclude patients in cardiogenic shock than those conducted outside of the U.S., as were studies that excluded patients with a previous myocardial infarction, studies published more recently, and smaller trials. Patients with cardiogenic shock have frequently been excluded from clinical trials of thrombolytic agents. As a result, data on the efficacy of thrombolytic agents in these patients is extremely limited.

Original languageEnglish (US)
Pages (from-to)149-157
Number of pages9
JournalThe American journal of cardiology
Volume73
Issue number2
DOIs
StatePublished - Jan 15 1994

Fingerprint

Cardiogenic Shock
Thrombolytic Therapy
Fibrinolytic Agents
Myocardial Infarction
Sample Size
Publications
Multivariate Analysis
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. / Col, Nananda F.; Gurwitz, Jerry H.; Alpert, Joseph S; Goldberg, Robert J.

In: The American journal of cardiology, Vol. 73, No. 2, 15.01.1994, p. 149-157.

Research output: Contribution to journalArticle

Col, Nananda F. ; Gurwitz, Jerry H. ; Alpert, Joseph S ; Goldberg, Robert J. / Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. In: The American journal of cardiology. 1994 ; Vol. 73, No. 2. pp. 149-157.
@article{0f17ca93f1cb4af88d31b8b575432613,
title = "Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy",
abstract = "The purpose of this study was to determine the extent to which patients with cardiogenic shock have participated in trials of thrombolytic therapy, to examine factors associated with their exclusion from these trials, and to summarize data on the efficacy of thrombolysis in these patients. Previous publications were searched for all randomized, controlled studies involving the use of thrombolytic medications used in the treatment of acute myocardial infarction. Data were abstracted for year of trial publication, performance location, sample size, maximal allowable delay between symptom onset and treatment, and exclusion criteria. Of the 94 trials included in the analysis, 22{\%} included patients with cardiogenic shock, 37{\%} excluded them, and the remainder contained no information on their inclusion or exclusion. Only 2 trials provided data on the efficacy of thrombolytic therapy in patients with cardiogenic shock. Multivariate analysis revealed that studies conducted exclusively in the U.S. were significantly more likely to exclude patients in cardiogenic shock than those conducted outside of the U.S., as were studies that excluded patients with a previous myocardial infarction, studies published more recently, and smaller trials. Patients with cardiogenic shock have frequently been excluded from clinical trials of thrombolytic agents. As a result, data on the efficacy of thrombolytic agents in these patients is extremely limited.",
author = "Col, {Nananda F.} and Gurwitz, {Jerry H.} and Alpert, {Joseph S} and Goldberg, {Robert J.}",
year = "1994",
month = "1",
day = "15",
doi = "10.1016/0002-9149(94)90206-2",
language = "English (US)",
volume = "73",
pages = "149--157",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy

AU - Col, Nananda F.

AU - Gurwitz, Jerry H.

AU - Alpert, Joseph S

AU - Goldberg, Robert J.

PY - 1994/1/15

Y1 - 1994/1/15

N2 - The purpose of this study was to determine the extent to which patients with cardiogenic shock have participated in trials of thrombolytic therapy, to examine factors associated with their exclusion from these trials, and to summarize data on the efficacy of thrombolysis in these patients. Previous publications were searched for all randomized, controlled studies involving the use of thrombolytic medications used in the treatment of acute myocardial infarction. Data were abstracted for year of trial publication, performance location, sample size, maximal allowable delay between symptom onset and treatment, and exclusion criteria. Of the 94 trials included in the analysis, 22% included patients with cardiogenic shock, 37% excluded them, and the remainder contained no information on their inclusion or exclusion. Only 2 trials provided data on the efficacy of thrombolytic therapy in patients with cardiogenic shock. Multivariate analysis revealed that studies conducted exclusively in the U.S. were significantly more likely to exclude patients in cardiogenic shock than those conducted outside of the U.S., as were studies that excluded patients with a previous myocardial infarction, studies published more recently, and smaller trials. Patients with cardiogenic shock have frequently been excluded from clinical trials of thrombolytic agents. As a result, data on the efficacy of thrombolytic agents in these patients is extremely limited.

AB - The purpose of this study was to determine the extent to which patients with cardiogenic shock have participated in trials of thrombolytic therapy, to examine factors associated with their exclusion from these trials, and to summarize data on the efficacy of thrombolysis in these patients. Previous publications were searched for all randomized, controlled studies involving the use of thrombolytic medications used in the treatment of acute myocardial infarction. Data were abstracted for year of trial publication, performance location, sample size, maximal allowable delay between symptom onset and treatment, and exclusion criteria. Of the 94 trials included in the analysis, 22% included patients with cardiogenic shock, 37% excluded them, and the remainder contained no information on their inclusion or exclusion. Only 2 trials provided data on the efficacy of thrombolytic therapy in patients with cardiogenic shock. Multivariate analysis revealed that studies conducted exclusively in the U.S. were significantly more likely to exclude patients in cardiogenic shock than those conducted outside of the U.S., as were studies that excluded patients with a previous myocardial infarction, studies published more recently, and smaller trials. Patients with cardiogenic shock have frequently been excluded from clinical trials of thrombolytic agents. As a result, data on the efficacy of thrombolytic agents in these patients is extremely limited.

UR - http://www.scopus.com/inward/record.url?scp=0028091234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028091234&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(94)90206-2

DO - 10.1016/0002-9149(94)90206-2

M3 - Article

C2 - 8296736

AN - SCOPUS:0028091234

VL - 73

SP - 149

EP - 157

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 2

ER -